Cellectis SA (NASDAQ:CLLS) has been given a consensus rating of “Buy” by the nine analysts that are presently covering the stock, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $31.33.
Several brokerages have recently issued reports on CLLS. BTIG Research began coverage on Cellectis in a research note on Friday, August 9th. They issued a “buy” rating and a $37.00 price target on the stock. Zacks Investment Research upgraded Cellectis from a “hold” rating to a “buy” rating and set a $15.00 price target on the stock in a research note on Tuesday. BidaskClub upgraded Cellectis from a “sell” rating to a “hold” rating in a research note on Tuesday. ValuEngine upgraded Cellectis from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Goldman Sachs Group set a $20.00 price target on Cellectis and gave the company a “hold” rating in a research note on Monday, August 12th.
CLLS stock traded down $0.16 during mid-day trading on Monday, reaching $13.53. The company had a trading volume of 88,900 shares, compared to its average volume of 99,222. Cellectis has a 52 week low of $9.50 and a 52 week high of $22.66. The stock has a 50 day simple moving average of $11.10 and a two-hundred day simple moving average of $14.10. The company has a debt-to-equity ratio of 0.12, a current ratio of 7.99 and a quick ratio of 7.93. The company has a market capitalization of $564.16 million, a price-to-earnings ratio of -7.01 and a beta of 1.77.
A number of hedge funds have recently modified their holdings of the stock. Cubist Systematic Strategies LLC bought a new stake in Cellectis during the 2nd quarter worth $103,000. Envestnet Asset Management Inc. grew its position in Cellectis by 22.1% during the 3rd quarter. Envestnet Asset Management Inc. now owns 50,228 shares of the biotechnology company’s stock worth $522,000 after acquiring an additional 9,088 shares during the last quarter. Aperio Group LLC bought a new stake in Cellectis during the 2nd quarter worth $147,000. A.R.T. Advisors LLC bought a new stake in Cellectis during the 2nd quarter worth $171,000. Finally, OneAscent Financial Services LLC bought a new stake in Cellectis during the 2nd quarter worth $257,000. Institutional investors and hedge funds own 32.13% of the company’s stock.
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.
Recommended Story: What is a capital gain?
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.